Morgan Stanley Issues Positive Forecast for BioMarin Pharmaceutical (NASDAQ:BMRN) Stock Price

BioMarin Pharmaceutical (NASDAQ:BMRN) had its price target raised by stock analysts at Morgan Stanley from $119.00 to $124.00 in a note issued to investors on Friday,Benzinga reports. The firm currently has an “overweight” rating on the biotechnology company’s stock. Morgan Stanley’s price objective indicates a potential upside of 96.17% from the stock’s previous close.

A number of other analysts also recently weighed in on BMRN. Royal Bank Of Canada decreased their target price on shares of BioMarin Pharmaceutical from $66.00 to $62.00 and set a “sector perform” rating for the company in a research report on Tuesday, July 7th. Citigroup increased their price objective on shares of BioMarin Pharmaceutical from $75.00 to $76.00 and gave the stock a “buy” rating in a research report on Thursday, July 16th. Bank of America lowered their target price on shares of BioMarin Pharmaceutical from $85.00 to $80.00 and set a “buy” rating for the company in a research note on Tuesday, May 19th. Wall Street Zen lowered shares of BioMarin Pharmaceutical from a “buy” rating to a “hold” rating in a report on Saturday, June 6th. Finally, HC Wainwright boosted their target price on shares of BioMarin Pharmaceutical from $50.00 to $60.00 and gave the company a “neutral” rating in a report on Friday. One research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and eight have given a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $87.86.

BioMarin Pharmaceutical Trading Up 2.8%

Shares of NASDAQ BMRN traded up $1.75 during trading on Friday, reaching $63.21. The company had a trading volume of 2,999,250 shares, compared to its average volume of 2,050,135. The company’s fifty day moving average price is $58.06 and its 200-day moving average price is $57.01. BioMarin Pharmaceutical has a 12 month low of $49.26 and a 12 month high of $66.28. The stock has a market cap of $12.22 billion, a P/E ratio of 46.06, a PEG ratio of 0.46 and a beta of 0.24. The company has a quick ratio of 4.20, a current ratio of 5.81 and a debt-to-equity ratio of 0.23.

BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its quarterly earnings results on Thursday, August 6th. The biotechnology company reported $1.20 earnings per share for the quarter, beating the consensus estimate of $0.95 by $0.25. BioMarin Pharmaceutical had a return on equity of 6.50% and a net margin of 8.29%.The company had revenue of $989.71 million during the quarter, compared to analysts’ expectations of $932.03 million. During the same quarter in the prior year, the firm posted $1.44 earnings per share. The business’s quarterly revenue was up 20.0% on a year-over-year basis. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. As a group, research analysts expect that BioMarin Pharmaceutical will post 4.22 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Pallas Capital Advisors LLC bought a new stake in BioMarin Pharmaceutical in the second quarter valued at $397,000. Deutsche Bank AG bought a new position in shares of BioMarin Pharmaceutical during the 2nd quarter worth about $7,226,000. Rice Hall James & Associates LLC bought a new position in shares of BioMarin Pharmaceutical during the 2nd quarter worth about $14,203,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in shares of BioMarin Pharmaceutical in the 2nd quarter valued at about $39,000. Finally, Monaco Asset Management SAM acquired a new stake in shares of BioMarin Pharmaceutical in the 2nd quarter valued at about $10,582,000. 98.71% of the stock is owned by institutional investors.

BioMarin Pharmaceutical News Summary

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: Q2 results exceeded expectations: BioMarin reported adjusted earnings of $1.20 per share, above the roughly $0.95–$0.96 analyst consensus, while revenue rose 20% year over year to approximately $990 million, surpassing estimates near $932 million. BioMarin Surpasses Q2 Earnings and Revenue Estimates
• Positive Sentiment: 2026 outlook was raised: The company now expects full-year adjusted EPS of $4.90–$5.10, above the prior consensus estimate of $4.80. Revenue guidance was set at approximately $3.9 billion, broadly in line with expectations. BMRN Stock Up as Q2 Earnings Beat on Sales Growth, 2026 Outlook Raised
• Positive Sentiment: Growth initiatives strengthened the longer-term outlook: Management highlighted continued momentum for VOXZOGO and the addition of Amicus products GALAFOLD and POMBILITI plus OPFOLDA. Expected cost synergies are projected to support revenue growth, earnings accretion, operating-margin expansion, and cash flow through the mid-2030s. BioMarin Reports Second Quarter 2026 Financial and Operating Results
• Neutral Sentiment: Although earnings beat estimates, quarterly EPS declined from $1.44 in the prior-year period, making the improved revenue trend and raised guidance important to sustaining investor enthusiasm. BioMarin Earnings Results and Conference Call
• Negative Sentiment: HC Wainwright raised its price target to $60 from $50 but retained a neutral rating. The new target remains below the stock’s recent trading level, signaling valuation concerns and limiting the strength of the analyst endorsement. Benzinga Analyst Rating Update

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.